

Gary J Nabel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7477406/gary-j-nabel-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95
papers

15,994
citations

62
h-index

109
g-index

109
ext. papers

18,000
ext. citations

22.1
avg, IF

6.03
L-index

#	Paper	IF	Citations
95	Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.. <i>Cell Reports</i> , 2022 , 38, 110199	10.6	3
94	A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells.. <i>Nature</i> , 2022 ,	50.4	8
93	A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice.. <i>Science Translational Medicine</i> , 2022 , 14, eabf3685	17.5	4
92	Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates. <i>Science Translational Medicine</i> , 2021 , 13,	17.5	15
91	Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models. <i>Science Translational Medicine</i> , 2021 , 13, eabc7804	17.5	14
90	A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. <i>Science Immunology</i> , 2020 , 5,	28	29
89	Design of a broadly reactive Lyme disease vaccine. <i>Npj Vaccines</i> , 2020 , 5, 33	9.5	24
88	Next-generation influenza vaccines: opportunities and challenges. <i>Nature Reviews Drug Discovery</i> , 2020 , 19, 239-252	64.1	81
87	Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation.. <i>Nature Cancer</i> , 2020 , 1, 86-98	15.4	68
86	Comparison of adjuvants to optimize influenza neutralizing antibody responses. <i>Vaccine</i> , 2019 , 37, 6208-6220	11.2	10
85	A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates. <i>Science Translational Medicine</i> , 2019 , 11,	17.5	16
84	Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells. <i>Immunity</i> , 2019 , 50, 1305-1316.e6	32.3	57
83	Gene delivery of a modified antibody to A β reduces progression of murine Alzheimer's disease. <i>PLoS ONE</i> , 2019 , 14, e0226245	3.7	11
82	Systemic immune-checkpoint blockade with anti-PD1 antibodies does not alter cerebral amyloid- β burden in several amyloid transgenic mouse models. <i>Glia</i> , 2018 , 66, 492-504	9	35
81	Development of a Pan-H1 Influenza Vaccine. <i>Journal of Virology</i> , 2018 , 92,	6.6	25
80	Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. <i>Science</i> , 2017 , 358, 85-90	33.3	176
79	Report of the Cent Gardes HIV Vaccines Conference. Part 1: The antibody response; Fondation Mieux Conference Center, Veyrier-du-Lac, France, 25-27 October 2015. <i>Vaccine</i> , 2016 , 34, 3557-61	4.1	1

78	H5N1 Vaccine-Elicited Memory B Cells Are Genetically Constrained by the IGHV Locus in the Recognition of a Neutralizing Epitope in the Hemagglutinin Stem. <i>Journal of Immunology</i> , 2015 , 195, 602-10	5.3	70
77	Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015 , 89, 5895-903	6.6	82
76	Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. <i>Vaccine</i> , 2015 , 33, 7344-7351	4.1	16
75	Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. <i>Cell</i> , 2015 , 162, 1090-100	56.2	181
74	Activation and lysis of human CD4 cells latently infected with HIV-1. <i>Nature Communications</i> , 2015 , 6, 8447	17.4	73
73	Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2015 , 89, 8334-45	6.6	81
72	Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. <i>Nature Medicine</i> , 2015 , 21, 1065-70	50.5	416
71	Phase 1 study of pandemic H1 DNA vaccine in healthy adults. <i>PLoS ONE</i> , 2015 , 10, e0123969	3.7	20
70	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014 , 505, 502-8	50.4	120
69	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014 , 211, 2061-74	16.6	245
68	Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. <i>Journal of Virology</i> , 2014 , 88, 12669-82	6.6	198
67	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014 , 514, 642-5	50.4	232
66	Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. <i>Journal of Virology</i> , 2014 , 88, 4047-57	6.6	153
65	Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. <i>Lancet, The</i> , 2014 , 384, 2046-52	40	165
64	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014 , 6, 243ra88	17.5	189
63	Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig-framework regions substantially reverted to germline. <i>Journal of Immunology</i> , 2014 , 192, 1100-1106	5.3	73
62	Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection. <i>PLoS ONE</i> , 2014 , 9, e87572	3.7	209
61	Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. <i>Immunity</i> , 2013 , 39, 245-58	32.3	254

60	Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. <i>Nature Reviews Immunology</i> , 2013 , 13, 693-701	36.5	255
59	Designing tomorrow's vaccines. <i>New England Journal of Medicine</i> , 2013 , 368, 551-60	59.2	199
58	Accelerating next-generation vaccine development for global disease prevention. <i>Science</i> , 2013 , 340, 1232-910	33.3	194
57	Outer domain of HIV-1 gp120: antigenic optimization, structural malleability, and crystal structure with antibody VRC-PG04. <i>Journal of Virology</i> , 2013 , 87, 2294-306	6.6	32
56	The need and challenges for development of an Epstein-Barr virus vaccine. <i>Vaccine</i> , 2013 , 31 Suppl 2, B194-6	4.1	62
55	Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. <i>Journal of Immunology</i> , 2013 , 190, 2720-27	5.3	74
54	Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. <i>Nature</i> , 2013 , 499, 102-6	50.4	481
53	Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. <i>Nature Structural and Molecular Biology</i> , 2013 , 20, 804-13	17.6	219
52	HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. <i>Nature</i> , 2013 , 498, 376-9	50.4	173
51	Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. <i>Journal of Infectious Diseases</i> , 2013 , 208, 418-22	7	94
50	Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. <i>Journal of Virology</i> , 2012 , 86, 7760-70	6.6	29
49	Elicitation of broadly neutralizing influenza antibodies in animals with previous influenza exposure. <i>Science Translational Medicine</i> , 2012 , 4, 147ra114	17.5	51
48	Structural and genetic basis for development of broadly neutralizing influenza antibodies. <i>Nature</i> , 2012 , 489, 566-70	50.4	188
47	The development of CD4 binding site antibodies during HIV-1 infection. <i>Journal of Virology</i> , 2012 , 86, 7588-95	6.6	105
46	Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination. <i>PLoS ONE</i> , 2012 , 7, e33969	3.7	21
45	Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. <i>Journal of Virology</i> , 2011 , 85, 9998-10009	6.6	342
44	Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. <i>Science</i> , 2011 , 333, 1593-602	33.3	688
43	CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. <i>Nature Medicine</i> , 2011 , 17, 1128-31	50.5	170

42	DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. <i>Lancet Infectious Diseases, The</i> , 2011 , 11, 916-24	25.5	161
41	Progress in the rational design of an AIDS vaccine. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2011 , 366, 2759-65	5.8	47
40	HIV-1 vaccines and adaptive trial designs. <i>Science Translational Medicine</i> , 2011 , 3, 79ps13	17.5	54
39	Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2011 , 1, a007278	5.4	114
38	Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. <i>Nature</i> , 2011 , 480, 336-43	43.4	682
37	Epstein-Barr virus: an important vaccine target for cancer prevention. <i>Science Translational Medicine</i> , 2011 , 3, 107fs7	17.5	224
36	A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. <i>Nature Medicine</i> , 2010 , 16, 334-8	50.5	332
35	Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. <i>Nature Medicine</i> , 2010 , 16, 1389-91	50.5	123
34	Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. <i>PLoS ONE</i> , 2010 , 5, e9015	3.7	118
33	Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. <i>Journal of Virology</i> , 2010 , 84, 630-8	6.6	48
32	Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. <i>Science</i> , 2010 , 329, 1060-4	33.3	289
31	Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. <i>Science Translational Medicine</i> , 2010 , 2, 24ra21	17.5	181
30	Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. <i>Science</i> , 2010 , 329, 811-7	33.3	871
29	Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. <i>Science</i> , 2010 , 329, 856-61	33.3	1327
28	Enhanced exposure of the CD4-binding site to neutralizing antibodies by structural design of a membrane-anchored human immunodeficiency virus type 1 gp120 domain. <i>Journal of Virology</i> , 2009 , 83, 5077-86	6.6	42
27	Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. <i>Journal of Virology</i> , 2009 , 83, 748-56	6.6	25
26	Low-dose rectal inoculation of rhesus macaques by SIVsmE660 or SIVmac251 recapitulates human mucosal infection by HIV-1. <i>Journal of Experimental Medicine</i> , 2009 , 206, 1117-34	16.6	257
25	A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. <i>Vaccine</i> , 2008 , 26, 6338-43	4.1	193

24	Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. <i>Journal of Virology</i> , 2008 , 82, 6200-8	6.6	121
23	Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells. <i>PLoS Pathogens</i> , 2007 , 3, e25	7.6	63
22	Immunization by avian H5 influenza hemagglutinin mutants with altered receptor binding specificity. <i>Science</i> , 2007 , 317, 825-8	33.3	185
21	Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 15987-91	11.5	69
20	Comparative immunogenicity of human immunodeficiency virus particles and corresponding polypeptides in a DNA vaccine. <i>Journal of Virology</i> , 2005 , 79, 626-31	6.6	8
19	Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. <i>Journal of Virology</i> , 2005 , 79, 771-9	6.6	96
18	HIV vaccine design and the neutralizing antibody problem. <i>Nature Immunology</i> , 2004 , 5, 233-6	19.1	659
17	Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. <i>Journal of Virology</i> , 2002 , 76, 5357-68	6.6	132
16	Development of molecular genetic interventions for HIV infection. <i>Current Protocols in Human Genetics</i> , 2001 , Chapter 13, Unit 13.6	3.2	
15	Immunization for Ebola virus infection. <i>Nature Medicine</i> , 1998 , 4, 37-42	50.5	189
14	Regulation of the proinflammatory effects of Fas ligand (CD95L). <i>Science</i> , 1998 , 282, 1714-7	33.3	292
13	The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. <i>Nature Medicine</i> , 1997 , 3, 333-7	50.5	76
12	Inhibition of the alloantibody response by CD95 ligand. <i>Nature Medicine</i> , 1997 , 3, 843-8	50.5	79
11	Calories lost--another mediator of cancer cachexia?. <i>Nature Medicine</i> , 1996 , 2, 397-8	50.5	5
10	Direct gene transfer for the understanding and treatment of human disease. <i>Annals of the New York Academy of Sciences</i> , 1994 , 716, 144-53	6.5	19
9	A molecular genetic intervention for AIDS--effects of a transdominant negative form of Rev. <i>Human Gene Therapy</i> , 1994 , 5, 79-92	4.8	56
8	Immunotherapy for cancer by direct gene transfer into tumors. <i>Human Gene Therapy</i> , 1994 , 5, 57-77	4.8	83
7	Liposome Mediated Gene Transfer into Vascular Cells. <i>Journal of Liposome Research</i> , 1993 , 3, 179-199	6.1	4

6	Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. <i>Nature</i> , 1993 , 362, 844-6	50.4	334
5	Immunotherapy of malignancy by in vivo gene transfer into tumors. <i>Human Gene Therapy</i> , 1992 , 3, 399-418	50.4	110
4	Cloning of an NF-kappa B subunit which stimulates HIV transcription in synergy with p65. <i>Nature</i> , 1991 , 352, 733-6	50.4	403
3	Extrachromosomal human immunodeficiency virus type-1 DNA can initiate a spreading infection of HL-60 cells. <i>Journal of Cellular Biochemistry</i> , 1991 , 45, 366-73	4.7	10
2	Activation of HIV gene expression during monocyte differentiation by induction of NF-kappa B. <i>Nature</i> , 1989 , 339, 70-3	50.4	546
1	HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. <i>Nature</i> , 1988 , 333, 776-8	50.4	587